Antidepressant adult suicidality committee
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will discuss the results of ongoing FDA meta-analyses of suicidality data from adult antidepressant trials during a Dec. 13 meeting. The panel, along with FDA's Pediatric Advisory Committee, reviewed data concerning the relationship between antidepressants and suicidal thoughts and actions in children and adolescents during two 2004 meetings (1"The Pink Sheet" Sept. 20, 2004, p. 3). The meeting will be held at the Hilton in Silver Spring, Md., beginning at 8 a.m....
You may also be interested in...
FDA Will Strengthen Antidepressant Warnings; “Black Box” Not Certain
FDA will require stronger warnings on antidepressants regarding the risk of pediatric suicidality following a Sept. 13-14 advisory committee review of the issue, but the agency is not yet ready to say that a "black box" will be necessary
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.